QualityStocks would like to highlight Nuvilex, Inc. (
OTCQB: NVLX), a biotechnology company. The live-cell encapsulation technology employed by Nuvilex is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Rather than encapsulating drugs, the technology is used for encapsulating living cells. Each capsule can enclose approximately 10,000 cells, depending upon the size of the cells. Depending on the type of cells used, the encapsulated cells can be employed in developing treatments for serious, debilitating, and even deadly diseases. Nuvilex’s primary interests in the use of the live-cell encapsulation technology are for the development of treatments for various cancers and for diabetes.
In the company’s news,
Nuvilex recently held three days of meetings set up to cement the company’s objectives, strategy, and plans for future research and development.
The meeting agenda called for heavy emphasis on the preparation for late-phase clinical trials of Nuvilex, which will use the recently acquired Cell-in-a-Box™ technology as part of the treatment for those suffering from advanced, inoperable pancreatic cancer. Nuvilex acquired the rights to this technology from SG Austria; the license for its use in diabetes was acquired by Nuvilex from Austrianova Singapore.
Also on the discussion table was the potential role that the live-cell encapsulation technology might play in developing treatments for diabetes, as well as in the development of treatments for diseases using active compounds derived from marijuana.
Meeting participants included the officers and board of directors of Nuvilex, as well as principals professor Walter H. Gunzburg, chairman and chief technical officer of SG Austria, and Dr. Brian Salmons, CEO and president of Austrianova Singapore.
Drs. Gunzburg and Salmons developed and brought to maturity the cellulose-based live-cell encapsulation technology that is the basis for Nuvilex’s research and development efforts. The doctors were also directly involved in the successful phase 1/2 clinical trials in advanced, inoperable pancreatic cancer already conducted using this technology.
Drs. Gunzburg and Salmons will continue to work closely with the company in projects that involve the use of this technology.
“These meetings were important and essential in cementing our plans for developing treatments for serious and deadly diseases like cancer and diabetes through the use of the cellulose-based live cell encapsulation technology,” Kenneth L Waggoner, Nuvilex’s CEO and president, stated in the news release. “In that vein, we are extremely grateful to Drs. Gunzburg and Salmons for traveling from Singapore to join us in them and for agreeing to work closely with us in our efforts to employ the technology that they have developed.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
